Novel Approach to the Formulation of an Epstein-Barr Virus Antigen-Based Nasopharyngeal Carcinoma Vaccine
- 1 January 2010
- journal article
- Published by American Society for Microbiology in Journal of Virology
- Vol. 84 (1), 407-417
- https://doi.org/10.1128/jvi.01303-09
Abstract
Epstein-Barr virus (EBV) is associated with several malignant diseases including nasopharyngeal carcinoma (NPC), a common neoplasm throughout southeast Asia. Radiotherapy and chemotherapy can achieve remission, but a reemergence of disease is not uncommon. Therefore, there is a need for specific therapies that target the tumor through the recognition of EBV antigens. In NPC, latent membrane protein 1 (LMP1) and LMP2 offer the best opportunity for specific targeting since they are typically expressed and T-cell determinants in each of these proteins have been defined. We have attempted to maximize the opportunity of incorporating every possible CD4 and CD8 determinant in a single formulation. We have achieved this by generating a scrambled protein incorporating random overlapping peptide sets from EBNA1, LMP1, and LMP2, which was then inserted into a replication-deficient strain of adenovirus (adenovirus scrambled antigen vaccine [Ad-SAVINE]). This report describes the construction of this Ad-SAVINE construct, its utility in generating LMP1 and LMP2 responses in healthy individuals as well as NPC patients, and its capacity to define new epitopes. This formulation could have a role in NPC immunotherapy for all ethnic groups since it has the potential to activate all possible CD4 and CD8 responses within EBNA1 and LMPs.Keywords
This publication has 51 references indexed in Scilit:
- Induction of Pluripotent Protective Immunity Following Immunisation with a Chimeric Vaccine against Human CytomegalovirusPLOS ONE, 2008
- Complete responses of relapsed lymphoma following genetic modification of tumor-antigen presenting cells and T-lymphocyte transferBlood, 2007
- Influence of translation efficiency of homologous viral proteins on the endogenous presentation of CD8+ T cell epitopesThe Journal of Experimental Medicine, 2007
- Cytotoxic T Lymphocyte Therapy for Epstein-Barr Virus+ Hodgkin's DiseaseThe Journal of Experimental Medicine, 2004
- Role of Cytotoxic T Lymphocytes in Epstein-Barr Virus-Associated DiseasesAnnual Review of Microbiology, 2000
- Restricted Low‐Level Human Antibody Responses against Epstein‐Barr Virus (EBV)–Encoded Latent Membrane Protein 1 in a Subgroup of Patients with EBV‐Associated DiseasesThe Journal of Infectious Diseases, 1999
- Restoration of endogenous antigen processing in Burkitt's lymphoma cells by Epstein‐Barr virus latent membrane protein‐1: coordinate up‐regulation of peptide transporters and HLA‐class I antigen expressionEuropean Journal of Immunology, 1995
- Localization of Epstein-Barr virus cytotoxic T cell epitopes using recombinant vaccinia: implications for vaccine development.The Journal of Experimental Medicine, 1992
- Identification of target antigens for the human cytotoxic T cell response to Epstein-Barr virus (EBV): implications for the immune control of EBV-positive malignancies.The Journal of Experimental Medicine, 1992
- Occupational and other non‐dietary risk factors for nasopharyngeal carcinoma in Guangzhou, ChinaInternational Journal of Cancer, 1990